Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

At Which Stage of Gastric Cancer Progression Do Levels of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Increase? Application in Advanced Gastric Cancer Treatment

  • Han, Eui Soo (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Lee, Han Hong (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jun Suh (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Song, Kyo Young (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Park, Cho Hyun (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Jeon, Hae Myung (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea)
  • Received : 2014.05.28
  • Accepted : 2014.06.22
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Since there are no proven tumor markers that reflect the course of gastric cancer, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are commonly used alternatives. However, the degree of progression that corresponds to an increase in these markers, and the values of these markers at different cancer stages, remains unclear. Materials and Methods: This study enrolled 1,733 gastric cancer patients who underwent surgery and whose pre-operative CEA and CA19-9 levels were known. Survival curves and mean values of the two markers were compared according to the degree of cancer progression: serosa-unexposed (SU), serosa-exposed (SE), direct invasion (DI), localized seeding (P1), and extensive seeding (P2). Results: The 5-year overall survival rates at each stage differed significantly, except between DI and P1 patients (17.1% vs. 10.5%, P=0.344). The mean CEA values in SU, SE, DI, P1, and P2 patients were 5.80, 5.48, 13.36, 8.06, and 22.82, respectively. The CA19-9 values for these patients were 49.40, 38.97, 101.67, 73.77, and 98.57, respectively. The increase in CEA in P2 patients was statistically significant (P=0.002), and the increases in CA19-9 in DI and P2 patients were significant (P=0.025, 0.007, respectively). There was a fair correlation between the two markers in P2 patients (r=0.494, P<0.001). Conclusions: CA19-9 can be used to assess DI of gastric cancer into adjacent organs. Both markers are useful for predicting the presence of extensive peritoneal seeding.

Keywords

References

  1. Sikaroodi M, Galachiantz Y, Baranova A. Tumor markers: the potential of "omics" approach. Curr Mol Med 2010;10:249-257. https://doi.org/10.2174/156652410790963277
  2. Seregni E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol 2001;20:147-166. https://doi.org/10.1002/ssu.1028
  3. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007;18:175-184. https://doi.org/10.1016/j.ejim.2006.12.001
  4. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856. https://doi.org/10.1038/nrc1739
  5. Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009;3:597-605. https://doi.org/10.1517/17530050903266830
  6. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011;58:239-245.
  7. Dilege E, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, et al. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterology 2010;57:674-677.
  8. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-2906.
  9. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33. https://doi.org/10.1007/s10120-013-0259-5
  10. Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis 2012;30:268-276. https://doi.org/10.1159/000336990
  11. Basbug M, Arikanoglu Z, Bulbuller N, Cetinkaya Z, Aygen E, Akbulut S, et al. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology 2011;58:400-405.
  12. Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-1432.
  13. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis 2007;9:527-531. https://doi.org/10.1111/j.1463-1318.2007.01176.x
  14. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012;23:1713-1722. https://doi.org/10.1093/annonc/mdr561
  15. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743. https://doi.org/10.1038/sj.bjc.6602760
  16. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9:735-740. https://doi.org/10.1097/00006676-199411000-00011
  17. Chen S, Feng XY, Li YF, Zhao BW, Zhou ZW, Chen YB. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol 2013;107:641-645. https://doi.org/10.1002/jso.23300
  18. Park SS, Min JS, Lee KJ, Jin SH, Park S, Bang HY, et al. Risk stratification for serosal invasion using preoperative predictors in patients with advanced gastric cancer. J Gastric Cancer 2012;12:149-155. https://doi.org/10.5230/jgc.2012.12.3.149
  19. Kang Y, Wang F, Zu H, Yang Z, Xue Y. A new subclassification of pT4 gastric cancers according to the width of serosal invasion. PLoS One 2013;8:e68042. https://doi.org/10.1371/journal.pone.0068042
  20. Shim JH, Yoo HM, Lee HH, Kim JG, Jeon HM, Song KY, et al. Use of laparoscopy as an alternative to computed tomography (CT) and positron emission tomography (PET) scans for the detection of recurrence in patients with gastric cancer: a pilot study. Surg Endosc 2011;25:3338-3344. https://doi.org/10.1007/s00464-011-1722-1
  21. Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH. Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. J Surg Oncol 2010;102:753-757. https://doi.org/10.1002/jso.21685

Cited by

  1. Preoperative Serum CEA and CA19-9 in Gastric Cancer - a Single Tertiary Hospital Study of 1,075 Cases vol.16, pp.7, 2014, https://doi.org/10.7314/apjcp.2015.16.7.2685
  2. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer vol.16, pp.9, 2014, https://doi.org/10.7314/apjcp.2015.16.9.3867
  3. Classic tumor markers in gastric cancer. Current standards and limitations vol.88, pp.2, 2014, https://doi.org/10.15386/cjmed-409
  4. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer vol.4, pp.3, 2016, https://doi.org/10.3892/mco.2015.712
  5. Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers vol.6, pp.1, 2014, https://doi.org/10.3390/biology6010016
  6. Stage Association of Preoperative Serum Carcinoembryonic Antigen with Gastric Adenocarcinoma in Iranian Patients vol.18, pp.10, 2017, https://doi.org/10.22034/apjcp.2017.18.10.2669
  7. Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors? vol.100, pp.4, 2014, https://doi.org/10.1308/rcsann.2018.0011
  8. Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites vol.19, pp.3, 2014, https://doi.org/10.5230/jgc.2019.19.e27
  9. Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application vol.12, pp.6, 2014, https://doi.org/10.3390/cancers12061509